Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein

Cat. No.   MHC-HM456

KACTUS

Description

Source	Recombinant Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus
	It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVGAVGVGK peptide.
Accession	NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVGAVGVGK
Molecular Weight	The protein has a predicted MW of 50.09 kDa. Due to glycosylation, the protein migrates to 52-65 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
	> 95% as determined by HPLC

Formulation and Storage

|	
Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Assay Data

Tris-Bis PAGE

Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein

Cat. No.   MHC-HM456

Assay Data

The purity of Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer is greater than 95% as determined by SEC-HPLC.